MHC class II-restricted T cell responses are a common driving force of autoimmune disease. Numerous therapeutic strategies target CD4+ T cells hoping to attenuate autoimmune responses and restore self-tolerance. We have previously reported that i.v. treatment with antigen-pulsed, ethylenecarbodiimide (ECDI)-fixed splenocytes (Ag-SP) is an efficient protocol to induce Ag-specific tolerance...